Alzheimers & Dementia

Papers
(The H4-Index of Alzheimers & Dementia is 59. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Issue Information2151
Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium1703
Cis p‐tau underlies vascular contribution to cognitive impairment and dementia, but is effectively targeted by immunotherapy871
814
RBFOX1 is regulated by the adenosine 2a receptor and is ubiquitinated in tau tangles in Alzheimer’s disease534
384
Melatonin, metformin, and ranolazine equally improved cognitive function in rats with doxorubicin‐induced chemobrain283
High‐fat diet reduced dendritic spine density, but it did not affect cognitive function in spontaneous diabetic torii rats275
Prevalence of neuropsychiatric conditions and cognitive impairment in two parallel, aging study cohorts from rural and urban India260
178
Reframing motherhood in dementia research: A call for action173
172
Cerebral small vessel disease burden and cognitive and functional outcomes after stroke: A multicenter prospective cohort study165
Why the cognitive “fountain of youth” may be upstream: Pathways to dementia risk and resilience through social connectedness162
Cerebrospinal fluid biomarkers in the Longitudinal Early‐onset Alzheimer's Disease Study161
Alzheimer's disease‐induced phagocytic microglia express a specific profile of coding and non‐coding RNAs157
Evaluation of major national dementia policies and health‐care system preparedness for early medical action and implementation147
Putting participants and study partners FIRST when clinical trials end early145
Entorhinal vessel density correlates with phosphorylated tau and TDP‐43 pathology136
Potential role of blood pressure variability and plasma neurofilament light in the mechanism of comorbidity between Alzheimer's disease and cerebral small vessel disease135
130
129
CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab124
ARMADA: Assessing reliable measurement in Alzheimer’s disease and cognitive aging project methods120
CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease118
Baseline characterization of the ARMADA (Assessing Reliable Measurement in Alzheimer's Disease) study cohorts118
Primary retinal tauopathy: A tauopathy with a distinct molecular pattern117
HbA1c variability associated with dementia risk in people with type 2 diabetes103
FDA‐approved carbonic anhydrase inhibitors reduce amyloid β pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness102
Intracranial arteriosclerosis and the risk of dementia: A population‐based cohort study98
Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study94
Lean mass, grip strength, and hospital‐associated disability among older adults in Health ABC92
Does Alzheimer's disease with mesial temporal lobe epilepsy represent a distinct disease subtype?91
Characterizing molecular and synaptic signatures in mouse models of late‐onset Alzheimer's disease independent of amyloid and tau pathology91
Dementias Platform UK: Bringing genetics into life83
Large‐scale proteome and metabolome analysis of CSF implicates altered glucose and carbon metabolism and succinylcarnitine in Alzheimer's disease77
Amyloid‐beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years75
Mendelian randomization highlights causal association between genetically increased C‐reactive protein levels and reduced Alzheimer's disease risk75
Issue Information74
Ethnic Disparities in Clinical Presentation of Patients with Early‐Onset Alzheimer’s Disease72
Combining high‐resolution ex vivo MRI and histopathology to identify medial temporal lobe atrophy patterns specific to tau pathology in Alzheimer’s Disease72
2021 Annual Report of Japanese Brain Bank Network for Neuroscience Research72
The relationship between cortical grey to white matter signal contrast (GWC) and tau pathology in atypical AD69
Characterising the covariance pattern between lifestyle factors and structural brain measures: a multivariable study of two cohorts of older adults69
Exploring Social Engagement in a Virtual Participatory Culinary Nutrition Education Intervention for Dementia Prevention68
Prevalence of Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) in the United States Medicare population67
In Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s Disease67
Reducing Risk of ADRDs: Innovative Framework to Inform Behavior Change65
Plasma biomarkers, memory impairment, and imaging measures of Alzheimer’s disease in American Indians65
Plasma phosphorylated tau 181 and modifiable risk factors for dementia in a large scale cohort of Australian older adults64
Brain‐Penetrable Antibody Probes for in vivo Tau Imaging64
Characterizing amyloid positive individuals with normal tau PET levels five years later: An ADNI study64
Is QEEG an effective biomarker in predicting cognitive decline?61
The association of gait velocity and cognitive performance in a sample of older Chinese Americans: A pilot study61
Racial disparities in Alzheimer’s Disease (AD): Correlating a novel neuropsychological screening test to established AD fluid and imaging biomarkers in African Americans and Caucasians60
Understanding differences in antidepressant use patterns among african american and white volunteers with dementia60
Prediction of amyloid‐beta accumulating normal cognitive elderly60
Prevalence and pathological correlates of unawareness of memory impairment in non‐demented individuals with autosomal dominant Alzheimer’s disease: an item‐level investigation of the Memory Complaints59
Ancestry‐Specific eQTL Associations in AA/NHW Alzheimer Disease Cohorts59
Quantitative amyloid PET in the AMYPAD diagnostic and patient management study59
0.10422515869141